Dear Editor,

We read with great interest a recent study by Yoshida et al. in Hypertension Research [1]. This study is an important contribution to the existing literature. By evaluating the therapeutic efficacy and safety of esaxerenone in patients with primary aldosteronism (PA), it fills the gap of information on this drug in the existing literature. Second, the study demonstrated the significant efficacy of esaxerenone in reducing systolic blood pressure, diastolic blood pressure, urinary albumin to creatinine ratio (UACR) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels, demonstrating its potential to improve cardiovascular and renal function. In addition, the significant improvement in patients’ quality of life scores after esaxerenone treatment was demonstrated by the Quality of Life Assessment, which provides an important reference for the comprehensive management of PA treatment in clinical practice. These findings not only enrich the understanding of PA treatment strategies, but also provide strong support for further optimization of individualized treatment plans in the future.